Methods and devices for controlled drug vaporization

ABSTRACT

The present invention an electronic inhaler for the delivery of pharmaceuticals through vaporization.

CROSS REFERENCE

This Application claims the benefit of U.S. Provisional Application No.62/329,351 filed on Apr. 29, 2016 and U.S. Provisional Application No.62/458,741 filed on Feb. 14, 2017, each of which is incorporated hereinby reference in its entirety.

BACKGROUND OF THE INVENTION

Delivery of pharmaceuticals through inhalation is a rapid process fortreating medical conditions because inhaled pharmaceuticals can beabsorbed quickly, and can act both locally and systemically. Inhalationis the most rapid way to deliver drugs to the brain, as the substancetravels directly to the brain without being diluted by circulation.Inhalation medical devices are also less invasive than other routes ofdrug administration, such as injection.

INCORPORATION BY REFERENCE

Each patent, publication, and non-patent literature cited in theapplication is hereby incorporated by reference in its entirety as ifeach was incorporated by reference individually.

SUMMARY OF THE INVENTION

In some embodiments, the invention comprises an inhalation devicecomprising: a) an outer compartment having an airflow pathway therein;b) a cartridge containing a first pharmaceutical, wherein the cartridgeis configured to pass a vapor of the first pharmaceutical to the airflowpathway; c) a heating element having a resistance of 0.2-3 Ohm, whereinthe heating element is configured to heat the first pharmaceutical,wherein the heating element is configured to be heated by passage of anelectrical current; and d) an oral administration port connected to theairflow pathway and configured to pass the vapor of the firstpharmaceutical from the airflow pathway to a user's mouth.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates examples of the foil heating element.

FIG. 2 illustrates examples of a serpentine-shaped foil heating element.

FIG. 3 illustrates an example of a heating foil attached to a holder forconnecting to an electrical and/or a mechanical connection.

FIG. 4 illustrates an embodiment of the device.

FIG. 5 illustrates an embodiment of the device.

FIG. 6 illustrates the rate of heating of the heating element usingthermal imaging.

DETAILED DESCRIPTION OF THE INVENTION

Electronic inhalation devices deliver chemicals, pharmaceuticals, andother substances to a subject by inhaled vapor. Generally, a personalinhalation device holds a medium that contains a drug and is atomizedwhen a user draws or puffs on the device, thereby creating a vaporcontaining the drug. The user inhales the vaporized substance.

Inhalation devices provide several advantages as an alternative tosmoked tobacco products. Inhaling a vapor containing nicotine canpreclude the tar and other harmful effects of traditional tobacco smoke.The vapor dissipates quickly, and reduces the hazards of secondhandsmoke. Inhalation devices avoid the fire hazard and environmentalproblems associated with tobacco smoking because no combustion isinvolved.

Inhalation devices can deliver uncontrolled and inconsistent dosages,which can raise regulatory issues. The present invention provides rapiddelivery of controlled quantities of drugs to the lung, and systemiccirculation, and the brain. This delivery provides rapid treatment ofmedical conditions including, for example, pain, breakthrough pain,cancer pain, anxiety, panic attacks, seizures, nausea, vomiting, loss ofappetite, and insomnia.

Provided herein are devices and methods for the delivery ofpharmaceuticals through heating and vaporization. The device comprises adisposable cartridge that contains a single dose of medicine coated on aheating element in an airway, and a reusable controller that contains abattery, integrated circuit, airflow path, and breath sensor. In thecartridge, the medicine resides as a thin film on the surface of aresistive element or on a thermal conductor in thermal contact with theresistive element. The cartridge and controller physically mate, and areelectrically connected, such that, upon activation of the breath sensor,the integrated circuit passes current from the battery to the resistiveelement in the cartridge. The resistive element heats and vaporizes thepharmaceutical, which cools and condenses in the airflow to form anaerosol suitable for inhalation.

Also provided herein are methods for manufacturing devices for deliveryof pharmaceuticals through vaporization.

Inhalation can draw the substance through the mouth, the nose, thepharynx, the trachea, or the lungs of a user. Non-limiting examples ofinhaled forms of the substance include a substance in the gaseous stateor a suspension of fine particles of liquid, solid, or both within a gasincluding, for example, aerosols, mists, and fumes.

In some embodiments, a substance can comprise a pharmaceutical compound.In some embodiments, the substance can comprise a therapeutic compoundor a non-therapeutic compound. A non-therapeutic compound can refer to acompound that can be used for recreational, experimental, orpre-clinical purposes. Classes of drugs that can be used include, butare not limited to, anesthetics, anticonvulsants, antidepressants,antidiabetic agents, antidotes, antiemetics, antihistamines,anti-infective agents, antineoplastics, antiparkinsonian drugs,antirheumatic agents, antipsychotics, anxiolytics, appetite stimulantsand suppressants, blood modifiers, cardiovascular agents, centralnervous system stimulants, drugs for Alzheimer's disease management,drugs for cystic fibrosis management, diagnostics, dietary supplements,drugs for erectile dysfunction, gastrointestinal agents, hormones, drugsfor the treatment of alcoholism, drugs for the treatment of addiction,immunosuppressives, mast cell stabilizers, migraine preparations, motionsickness products, drugs for multiple sclerosis management, musclerelaxants, nonsteroidal anti-inflammatories, opioids, other analgesicsand stimulants, ophthalmic preparations, osteoporosis preparations,prostaglandins, respiratory agents, sedatives and hypnotics, skin andmucous membrane agents, smoking cessation aids, Tourette's syndromeagents, urinary tract agents, and vertigo agents.

In some embodiments, an anesthetic can be selected from one of thefollowing compounds: ketamine and lidocaine.

In some embodiments, an anticonvulsant can be selected from one of thefollowing classes: GABA analogs, tiagabine, vigabatrin; barbituratessuch as pentobarbital; benzodiazepines such as clonazepam; hydantoinssuch as phenytoin; phenyltriazines such as lamotrigine; miscellaneousanticonvulsants, such as carbamazepine, topiramate, valproic acid, andzonisamide.

In some embodiments, an antidepressant can be selected from one of thefollowing compounds: amitriptyline, amoxapine, benmoxine, butriptyline,clomipramine, desipramine, dosulepin, doxepin, imipramine, kitanserin,lofepramine, medifoxamine, mianserin, maprotoline, mirtazapine,nortriptyline, protriptyline, trimipramine, venlafaxine, viloxazine,citalopram, cotinine, duloxetine, fluoxetine, fluvoxamine, milnacipran,nisoxetine, paroxetine, reboxetine, sertraline, tianeptine,acetaphenazine, binedaline, brofaromine, cericlamine, clovoxamine,iproniazid, isocarboxazid, moclobemide, phenyhydrazine, phenelzine,selegiline, sibutramine, tranylcypromine, ademetionine, adrafinil,amesergide, amisulpride, amperozide, benactyzine, bupropion, caroxazone,gepirone, idazoxan, metralindole, milnacipran, minaprine, nefazodone,nomifensine, ritanserin, roxindole, S-adenosylmethionine, escitalopram,tofenacin, trazodone, tryptophan, and zalospirone.

In some embodiments, an antidiabetic agent can be selected from one ofthe following compounds: pioglitazone, rosiglitazone, and troglitazone.

In some embodiments, an antidote can be selected from one of thefollowing compounds: edrophonium chloride, flumazenil, deferoxamine,nalmefene, naloxone, and naltrexone.

In some embodiments, an antiemetic can be selected from one of thefollowing compounds: alizapride, azasetron, benzquinamide, bromopride,buclizine, chlorpromazine, cinnarizine, clebopride, cyclizine,diphenhydramine, diphenidol, dolasetron, droperidol, granisetron,hyoscine, lorazepam, dronabinol, metoclopramide, metopimazine,ondansetron, perphenazine, promethazine, prochlorperazine, scopolamine,triethylperazine, trifluoperazine, triflupromazine, trimethobenzamide,tropisetron, domperidone, and palonosetron.

In some embodiments, an antihistamine can be selected from one of thefollowing compounds: astemizole, azatadine, brompheniramine,carbinoxamine, cetrizine, chlorpheniramine, cinnarizine, clemastine,cyproheptadine, dexmedetomidine, diphenhydramine, doxylamine,fexofenadine, hydroxyzine, loratidine, promethazine, pyrilamine andterfenidine.

In some embodiments, an anti-infective agent can be selected from one ofthe following classes: antivirals such as efavirenz; AIDS adjunct agentssuch as dapsone; aminoglycosides such as tobramycin; antifungals such asfluconazole; antimalarial agents such as quinine; antituberculosisagents such as ethambutol; β-lactams such as cefinetazole, cefazolin,cephalexin, cefoperazone, cefoxitin, cephacetrile, cephaloglycin,cephaloridine; cephalosporins, such as cephalosporin C, cephalothin;cephamycins such as cephamycin A, cephamycin B, and cephamycin C,cephapirin, cephradine; leprostatics such as clofazimine; penicillinssuch as ampicillin, amoxicillin, hetacillin, carfecillin, carindacillin,carbenicillin, amylpenicillin, azidocillin, benzylpenicillin,clametacillin, cloxacillin, cyclacillin, methicillin, nafcillin,2-pentenylpenicillin, penicillin N, penicillin O, penicillin S,penicillin V, dicloxacillin; diphenicillin; heptylpenicillin; andmetampicillin; quinolones such as ciprofloxacin, clinafloxacin,difloxacin, grepafloxacin, norfloxacin, ofloxacine, temafloxacin;tetracyclines such as doxycycline and oxytetracycline; miscellaneousanti-infectives such as linezolide, trimethoprim and sulfamethoxazole.

In some embodiments, an anti-neoplastic agent can be selected from oneof the following compounds: droloxifene, tamoxifen, and toremifene.

In some embodiments, an antiparkisonian drug can be selected from one ofthe following compounds: amantadine, baclofen, biperiden, benztropine,orphenadrine, procyclidine, trihexyphenidyl, levodopa, carbidopa,andropinirole, apomorphine, benserazide, bromocriptine, budipine,cabergoline, eliprodil, eptastigmine, ergoline, galanthamine,lazabemide, lisuride, mazindol, memantine, mofegiline, pergolide,piribedil, pramipexole, propentofylline, rasagiline, remacemide,ropinerole, selegiline, spheramine, terguride, entacapone, andtolcapone.

In some embodiments, an antirheumatic agent can be selected from one ofthe following compounds: diclofenac, hydroxychloroquine andmethotrexate.

In some embodiments, an antipsychotic can be selected from one of thefollowing compounds: acetophenazine, alizapride, amisulpride, amoxapine,amperozide, an piprazole, benperidol, benzquinamide, bromperidol,buramate, butaclamol, butaperazine, carphenazine, carpipramine,chlorpromazine, chlorprothixene, clocapratnine, clomacran, clopenthixol,clospirazine, clothiapine, clozapine, cyamemazine, droperidol,flupenthixol, fluphenazine, fluspirilene, haloperidol, loxapine,melperone, mesoridazine, metofenazate, molindrone, olanzapine,penfluridol, pericyazine, perphenazine, pimozide, pipamerone,piperacetazine, pipotiazine, prochlorperazine, promazine, quetiapine,remoxipride, risperidone, sertindole, spiperone, sulpiride,thioridazine, thiothixene, trifluperidol, triflupromazine,trifluoperazine, ziprasidone, zotepine, and zuclopenthixol.

In some embodiments, an anxiolytic can be selected from one of thefollowing compounds: alprazolam, bromazepam, oxazepam, buspirone,hydroxyzine, mecloqualone, medetomidine, metomidate, adinazolam,chlordiazepoxide, clobenzepam, flurazepam, lorazepam, loprazolam,midazolam, alpidem, alseroxlon, amphenidone, azacyclonol, bromisovalum,captodiamine, capuride, carbcloral, carbromal, chloral betaine,enciprazine, flesinoxan, ipsapiraone, lesopitron, loxapine,methaqualone, methprylon, propanolol, tandospirone, trazadone,zopiclone, and zolpidem.

In some embodiments, an appetite stimulant can be dronabinol.

In some embodiments, an appetite suppressant can be selected from one ofthe following compounds: fenfluramine, phentermine, and sibutramine.

In some embodiments, a blood modifier can be selected from one of thefollowing compounds: cilostazol, and dipyridamol.

In some embodiments, a cardiovascular agent can be selected from one ofthe following compounds: benazepril, captopril, enalapril, quinapril,ramipril, doxazosin, prazosin, clonidine, labetolol, candesartan,irbesartan, losartan, telmisartan, valsartan, disopyramide, flecanide,mexiletine, procainamide, propafenone, quinidine, tocainide, amiodarone,dofetilide, ibutilide, adenosine, gemfibrozil, lovastatin, acebutalol,atenolol, bisoprolol, esmolol, metoprolol, nadolol, pindolol,propranolol, sotalol, diltiazem, nifedipine, verapamil, spironolactone,bumetanide, ethacrynic acid, furosemide, torsemide, amiloride,triamterene, and metolazone.

In some embodiments, a central nervous system stimulant can be selectedfrom one of the following compounds: amphetamine, brucine, caffeine,dexfenfluramine, dextroamphetamine, ephedrine, fenfluramine, mazindol,methyphenidate, pemoline, phentermine, sibutramine, and modafinil.

In some embodiments, a drug for Alzheimer's disease management can beselected from one of the following compounds: donepezil, galanthamine,and tacrin.

In some embodiments, a drug for cystic fibrosis management can beselected from one of the following compounds: CPX, IBMX, XAC, andanalogues; 4-phenylbutyric acid; genistein and analogous isoflavones;and milrinone.

In some embodiments, a diagnostic agent can be selected from one of thefollowing compounds: adenosine and aminohippuric acid.

In some embodiments, a dietary supplement can be selected from one ofthe following compounds: melatonin and vitamin-E.

In some embodiments, a drug for erectile dysfunction can be selectedfrom one of the following compounds: tadalafil, sildenafil, vardenafil,apomorphine, apomorphine diacetate, phentolamine, and yohimbine.

In some embodiments, a gastrointestinal agent can be selected from oneof the following compounds: loperamide, atropine, hyoscyamine,famotidine, lansoprazole, omeprazole, and rebeprazole.

In some embodiments, a hormone can be selected from one of the followingcompounds: testosterone, estradiol, and cortisone.

In some embodiments, a drug for the treatment of alcoholism can beselected from one of the following compounds: naloxone, naltrexone, anddisulfiram.

In some embodiments, a drug for the treatment of addiction can bebuprenorphine.

In some embodiments, an immunosuppressive can be selected from one ofthe following compounds: mycophenolic acid, cyclosporin, azathioprine,tacrolimus, and rapamycin.

In some embodiments, a mast cell stabilizer can be selected from one ofthe following compounds: cromolyn, pemirolast, and nedocromil.

In some embodiments, a drug for migraine headache can be selected fromone of the following compounds: almotriptan, alperopride, codeine,dihydroergotamine, ergotamine, eletriptan, frovatriptan, isometheptene,lidocaine, lisuride, metoclopramide, naratriptan, oxycodone,propoxyphene, rizatriptan, sumatriptan, tolfenamic acid, zolmitriptan,amitriptyline, atenolol, clonidine, cyproheptadine, diltiazem, doxepin,fluoxetine, lisinopril, methysergide, metoprolol, nadolol,nortriptyline, paroxetine, pizotifen, pizotyline, propanolol,protriptyline, sertraline, timolol, and verapamil.

In some embodiments, a motion sickness product can be selected from oneof the following compounds: diphenhydramine, promethazine, andscopolamine.

In some embodiments, a drug for multiple sclerosis management can beselected from one of the following compounds: bencyclane,methylprednisolone, mitoxantrone, and prednisolone.

In some embodiments, a muscle relaxant can be selected from one of thefollowing compounds: baclofen, chlorzoxazone, cyclobenzaprine,methocarbamol, orphenadrine, quinine, and tizanidine.

In some embodiments, a nonsteroidal anti-inflammatory can be selectedfrom one of the following compounds: aceclofenac, acetaminophen,alminoprofen, amfenac, aminopropylon, amixetrine, aspirin, benoxaprofen,bromfenac, bufexamac, carprofen, celecoxib, choline, salicylate,cinchophen, cinmetacin, clopriac, clometacin, diclofenac, diflunisal,etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, indoprofen,ketoprofen, ketorolac, mazipredone, meclofenamate, nabumetone, naproxen,parecoxib, piroxicam, pirprofen, rofecoxib, sulindac, tolfenamate,tolmetin, and valdecoxib.

In some embodiments, an opioid can be selected from one of the followingcompounds: alfentanil, allylprodine, alphaprodine, anileridine,benzylmorphine, bezitramide, buprenorphine, butorphanol, carbiphene,cipramadol, clonitazene, codeine, dextromoramide, dextropropoxyphene,diamorphine, dihydrocodeine, diphenoxylate, dipipanone, fentanyl,hydromorphone, L-alpha acetyl methadol, lofentanil, levorphanol,meperidine, methadone, meptazinol, metopon, morphine, nalbuphine,nalorphine, oxycodone, papaveretum, pethidine, pentazocine, phenazocine,remifentanil, sufentanil, and tramadol.

In some embodiments, another analgesic can be selected from one of thefollowing compounds: apazone, benzpiperylon, benzydramine, caffeine,clonixin, ethoheptazine, flupirtine, nefopam, orphenadrine,propacetamol, and propoxyphene.

In some embodiments, an opthalmic preparation can be selected from oneof the following compounds: ketotifen and betaxolol.

In some embodiments, an osteoporosis preparation can be selected fromone of the following compounds: alendronate, estradiol, estropitate,risedronate and raloxifene.

In some embodiments, a prostaglandin can be selected from one of thefollowing compounds: epoprostanol, dinoprostone, misoprostol, andalprostadil.

In some embodiments, a respiratory agent can be selected from one of thefollowing compounds: albuterol, ephedrine, epinephrine, fomoterol,metaproterenol, terbutaline, budesonide, ciclesonide, dexamethasone,flunisolide, fluticasone propionate, triamcinolone acetonide,ipratropium bromide, pseudoephedrine, theophylline, montelukast,zafirlukast, ambrisentan, bosentan, enrasentan, sitaxsentan, tezosentan,iloprost, treprostinil, and pirfenidone

In some embodiments, a sedative and hypnotic can be selected from one ofthe following compounds: butalbital, chlordiazepoxide, diazepam,estazolam, flunitrazepam, flurazepam, lorazepam, midazulam temazepam,triazolam, zaleplon, zolpidem, and zopiclone.

In some embodiments, a skin and mucous membrane agent can be selectedfrom one of the following compounds: isotretinoin, bergapten andmethoxsalen.

In some embodiments, a smoking cessation aid can be selected from one ofthe following compounds: nicotine and varenicline.

In some embodiments, a Tourette's syndrome agent can be pimozide.

In some embodiments, a urinary tract agent can be selected from one ofthe following compounds: tolteridine, darifenicin, propanthelinebromide, and oxybutynin.

In some embodiments, a vertigo agent can be selected from one of thefollowing compounds: betahistine and meclizine.

In general, a suitable drug can have properties that make themacceptable candidates for use with the devices and methods hereindescribed. For example, the drug compound can be one that is, or can bemade to be, vaporizable. In some embodiments, the drug is a heat-stabledrug. Exemplary drugs include acebutolol, acetaminophen, alprazolam,amantadine, amitriptyline, apomorphine diacetate, apomorphinehydrochloride, atropine, azatadine, betahistine, brompheniramine,bumetanide, buprenorphine, bupropion hydrochloride, butalbital,butorphanol, carbinoxamine maleate, celecoxib, chlordiazepoxide,chlorpheniramine, chlorzoxazone, ciclesonide, citalopram, clomipramine,clonazepam, clozapine, codeine, cyclobenzaprine, cyproheptadine,dapsone, diazepam, diclofenac ethyl ester, diflunisal, disopyramide,doxepin, estradiol, ephedrine, estazolam, ethacrynic acid, fenfluramine,fenoprofen, flecainide, flunitrazepam, galanthamine, granisetron,haloperidol, hydromorphone, hydroxychloroquine, ibuprofen, imipramine,indomethacin ethyl ester, indomethacin methyl ester, isocarboxazid,ketamine, ketoprofen, ketoprofen ethyl ester, ketoprofen methyl ester,ketorolac ethyl ester, ketorolac methyl ester, ketotifen, lamotrigine,lidocaine, loperamide, loratadine, loxapine, maprotiline, memantine,meperidine, metaproterenol, methoxsalen, metoprolol, mexiletine HCl,midazolam, mirtazapine, morphine, nalbuphine, naloxone, naproxen,naratriptan, nortriptyline, olanzapine, orphenadrine, oxycodone,paroxetine, pergolide, phenytoin, pindolol, piribedil, pramipexole,procainamide, prochloperazine, propafenone, propranolol, pyfilamine,quetiapine, quinidine, rizatriptan, ropinirole, sertraline, selegiline,sildenafil, spironolactone, tacrine, tadalafil, terbutaline,testosterone, thalidomide, theophylline, tocainide, toremifene,trazodone, triazolam, trifluoperazine, valproic acid, venlafaxine,vitamin E, zaleplon, zotepine, amoxapine, atenolol, benztropine,caffeine, doxylamine, estradiol 17-acetate, flurazepam, flurbiprofen,hydroxyzine, ibutilide, indomethacin norcholine ester, ketorolacnorcholine ester, melatonin, metoclopramide, nabumetone, perphenazine,protriptyline HCl, quinine, triamterene, trimipramine, zonisamide,bergapten, chlorpromazine, colchicine, diltiazem, donepezil, eletriptan,estradiol-3,17-diacetate, efavirenz, esmolol, fentanyl, flunisolide,fluoxetine, hyoscyamine, indomethacin, isotretinoin, linezolid,meclizine, paracoxib, pioglitazone, rofecoxib, sumatriptan, tolterodine,tramadol, tranylcypromine, trimipramine maleate, valdecoxib, vardenafil,verapamil, zolmitriptan, zolpidem, zopiclone, bromazepam, buspirone,cinnarizine, dipyridamole, naltrexone, sotalol, telmisartan, temazepam,albuterol, apomorphine hydrochloride diacetate, carbinoxamine,clonidine, diphenhydramine, thambutol, fluticasone proprionate,fluconazole, lovastatin, lorazepam N,O-diacetyl, methadone, nefazodone,oxybutynin, promazine, promethazine, sibutramine, tamoxifen, tolfenamicacid, aripiprazole, astemizole, benazepril, clemastine, estradiol17-heptanoate, fluphenazine, protriptyline, ethambutal, frovatriptan,pyrilamine maleate, scopolamine, triamcinolone acetonide, andpharmaceutically acceptable analogs and equivalents thereof.

Non-limiting examples of pharmaceutical compounds include fluticasonepropionate, clonidine, triazolam, albuterol, ciclesonide, fentanyl,terbutaline, flumazenil, triamcinolone acetonide, flunisolide,ropinirole, alprazolam, buprenorphine, hyoscyamine, atropine,pramipexole, bumetanide, flunitrazepam, oxymorphone, colchicine,apomorphine HCl, granisetron, pergolide, nicotine, loperamide,azatadine, naratriptan, clemastine, benztropine, ibutilide, butorphanol,fluphenazine, estradiol-17-heptanoate, zolmitriptan, metaproterenol,scopolamine, diazepam, tolterodine, estazolam, haloperidol,carbinoxamine, estradiol, hydromorphone, bromazepam, perphenazine,midazolam, methadone, frovatriptan, eletriptan, testosterone, melatonin,galanthamine, cyproheptadine, bropheniramine, and chlorpheniramine. Incertain embodiments, the compound is chosen from alprazolam,buprenorphine, clonindine, fentanyl, midazolam, pramipexole, ropinirole,and triazolam. In some embodiments, the compound is chosen from acompound for the treatment of pain. In some embodiments, the compoundfor the treatment of pain is fentanyl.

In some embodiments, the pharmaceutical delivered by the inhaler is anopioid agonist or a partial opioid agonist, a benzodiazepine, acannabinoid agonist, or partial agonist. Non-limiting examples of opioidagonists include fentanyl, sufentanil, buprenorphine, hydromorphone,morphine, oxycodone, tramadol, methadone, hydrocodone, oxycodone,meperidine, oxymorphone, tapentadol, propoxyphene, remifentanil,nutorphanol, alfentanil, and levorphanol. Non-limiting examples ofbenzodiazepines include alprazolam, triazolam, and midazolam.Non-limiting examples of cannabinoids include tetrahydrocannabinol (THC)and cannabidiol (CBD).

In some embodiments, drugs can be formulated as the free base or freeacid form to facilitate vaporization. A drug can be formulated as aprodrug or a drug precursor, which forms the active drug substance uponheating or upon metabolism. For example, tetrahydrocannabinolic acid(THCA) is more stable than THC, and THCA forms THC upon heating andvaporization. Esters of carboxylic acids are more volatile than theassociated free acids, and can vaporize more efficiently. These esterscan metabolize in the body into the free acids.

In some embodiments, the dosage of the medication provided by the deviceis about 25 μg, about 50 μg, about 100 μg, about 200 μg, about 250 μg,about 500 μg, or about 1000 μg in a single inhalation. In someembodiments, the thickness of the drug coating is about 1 μm, about 2μm, about 3 μm, about 4 μm, about 8 μm, about 12 μm, about 15 μm, orabout 20 μm. In some embodiments, the heating of the heating element issufficient to vaporize essentially all or most of the drug coating, forexample, at least 90%, at least 95%, at least 98%, or at least 99%, suchthat the emitted dose from the device is determined by the thickness ofthe coating multiplied by the coated surface area (SA): dose (μg)=SA(mm³)*thickness (μm)*density (mg/mm³). In some embodiments, the heatingelement is a foil. For example, a dose of 100 μg of fentanyl can beadministered using a surface area of 20 mm³ achieved as a 1 mm×20 mmstainless steel foil coated on a single side, at a thickness of 5 μm.The drug can be fully vaporized within about 0.2 s, about 0.4 s, about0.6 s, about 0.8 s, about 1 s, or about 1.5 s of activation of thebreath sensor.

In some embodiments, a cartridge contains only one foil. An advantage ofhaving a cartridge containing only one foil is that using one foilremoves the possibility of cross-contamination between foils duringeither storage or dosing. In addition, the cartridge can be packaged asrequired to maintain purity and performance (for example, within apolymer and/or metal pouch, including as appropriate barrier materialssuch as aluminum, polyethylene terephthalate, and barex), and removedfrom the packaging only at the time that the foil will be used,obviating concerns about stability of the foil after the removal of thefoil from the packaging. In some embodiments, a cartridge contains morethan one foil. If each foil is designed to deliver one dose ofmedication, then the drug vaporized during activation of a first foil todeliver a first dose of medication can potentially deposit onto anotherfoil. Subsequent activation of the second foil can result in delivery ofa dose that is greater than the intended dose, and can be a safety andregulatory concern. Moreover, repeated vaporization of the drug canresult in degradation products that would not otherwise occur in adevice containing only one foil. In some embodiments, the geometry andairflow are optimized to avoid excessive re-deposition of the vaporizeddrug onto other foils.

In some embodiments, a cartridge contains only one foil to lessen thelikelihood of overdose, to ensure repeated dose reproducibility, tosimplify product testing to meet regulatory requirements, to obviateconcerns about the stability of additional foils after use of one ormore foils within a cartridge, and/or other reasons. In someembodiments, a cartridge contains more than one foil. A cartridgecontaining more than one foil can heat at different times and can, inthe case of simultaneous heating of multiple files orcross-contamination between foils, deliver a dose that is greater thanthe prescribed dose.

To achieve drug vaporization, the temperature of the drug coating can beraised through a heating element. The heating element can increase thetemperature substantially above room temperature of the surface to whichthe drug coating is in thermal contact. For example, the temperature ofthe surface can increase to about 100° C., about 150° C., about 200° C.,about 250° C., about 300° C., about 350° C., about 400° C., about 450°C., or about 500° C. For a drug that is prone to thermal degradation,the surface temperature can be kept below about 400° C., 450° C., about500° C., about 550° C., or about 600° C. to avoid the release ofundesirable byproducts or degradation. Vaporization of drug from thesurface results in evaporative cooling, which helps control the surfacetemperature until the drug is fully or partially vaporized. Properheating can be accomplished by an appropriate pairing of battery,heating element, and controller electronics.

In some embodiments, the battery can be a lithium ion, lithium ionpolymer, lead-acid, nickel cadmium, or a nickel metal hydride battery.The battery can produce a voltage in the range of about 3 V to about 4V. In some embodiments, the operating voltage of the battery is about 3V, about 3.1 V, about 3.2 V, about 3.3 V, about 3.4 V, about 3.5 V,about 3.6 V, about 3.7 V, about 3.8 V, about 3.9 V, or about 4 V. Insome embodiments, the electrical resistance of the heating element is inthe range of about 1-3 Ohm. In some embodiments, the electricalresistance of the heating element is in the range of about 1.4-2.8 Ohm.In some embodiments, the electrical resistance of the heating element isin the range of about 0.2-1.0 Ohm. In some embodiments, the electricalresistance of the heating element is about 0.2 Ohm, about 0.3 Ohm, about0.4 Ohm, about 0.5 Ohm, about 0.75 Ohm, about 1 Ohm, about 1.2 Ohm,about 1.5 Ohm, about 2 Ohm, about 2.5 Ohm, about 3 Ohm, about 4 Ohm,about 5 Ohm, about 7.5 Ohm, or about 10 Ohm. In some embodiments, thecontroller can employ pulse width modulation to pass currentintermittently through, and heat, the foil.

In some embodiments of a pulse sequence, the controller can initiallydeliver longer or more frequent pulses, and thereafter, deliver shorteror less frequent pulses to achieve rapid initial heating followed byless rapid subsequent heating to avoid overheating of the drug or thedevice. In some embodiments, the controller can deliver an average poweroutput of greater than 50% or 75% of the maximal output (given thebattery and circuit resistance, P_(max)=V²/R) over a first duration, andcan deliver an average power part of less than 50% or 75% of the maximaloutput over a second duration. In some embodiments, the first durationis at least 0.1 s and no greater than 2 s. In some embodiments, thefirst duration is about 0.1, about 0.2, about 0.3, about 0.5, about 0.7,about 1, about 1.5, or about 2 s. In some embodiments, the secondduration begins immediately at the end of the first duration andcontinues until termination of heating. In some embodiments, heatingturns off when the breath sensor detects the end of inhalation. In someembodiments, heating turns off after a predetermined duration. In someembodiments, the predetermined duration is chosen to be about 0.1 s,about 0.2 s, about 0.5 s, or about 1 s longer than the time required tofully vaporize the drug on the foil when the device is used at thecoolest relevant environmental temperature (i.e., the bottom end of thetemperature range recommended on the packaging for use of the product).

In some embodiments, the device includes a closed-loop sensor to monitorthe temperature of the heating element and adjust the electrical flowaccordingly. In some embodiments, the duration of the pulses isdetermined in part by the voltage of the battery, such that when thebattery voltage is lower, the pulses are longer or more frequent, andwhen the battery voltage is higher, the pulses are shorter or lessfrequent. The overall effect is a consistent heating mechanism resistantto small variations in the battery voltage as may occur with shelf-lifestorage or repeated use of the battery.

The device can be made of a variety of materials and have a variety ofshapes. In some embodiments, the exterior of the device is made of amedical grade polymer.

The heating element of the device can be made of a variety of materialsand have a variety of shapes, while achieving: (i) a suitable electricalresistance to provide efficient heating, (ii) a suitable thermal masssuitable for effective heating by the battery, (iii) a suitable surfacearea for drug vaporization, and (iv) surface chemistry suitable for drugadherence and to avoid surface-catalyzed drug degradation during eithershelf-life storage or the heating and vaporization process. Non-limitingexamples of materials that can serve directly as both electricalresistors and supports for the drug vaporization include nichrome andstainless steel.

The electrical resistance of the heating element is determined by boththe material and the geometry. For example, for the 1 mm×20 mm stainlesssteel foil described above, with electrical connections at the distalends (i.e. 20 mm apart), using an alloy of stainless steel withresistance of 10e⁻⁶ Ohm and a stainless steel foil thickness of 0.0005″(0.012 mm), the resistance is 1.6 Ohm. Power output is given by V²/R,resulting, at an operating voltage of 3.5 V in a power output of 7.7 W.The mass of the 1 mm×20 mm×0.012 mm stainless steel foil is 1.92 mg,which, at a heat capacity of 0.5 J/gK, is suitable for heating the foilby 400° C. with 0.38 J, i.e. over 50 ms at 7.7 W. Slower and morecontrolled heating can occur by delivering the 0.38 J over 100 msthrough on-and-off pulses, followed by continued heating over the next 1s at a reduced rate due to a schedule of off periods with relativelybriefer on pulses.

Another example of geometry and material is a nichrome wire of length 40mm and a diameter of 0.18 mm. Such a wire has a resistance of about 1.6Ohm, a surface area of about 22 mm², and a mass of 8 mg, resulting in arequirement for 1.6 J of energy to heat the wire by 400° C. At 3.6 V,such heating can be achieved over 200 ms in the absence of pulse widthmodulation.

In some embodiments, the thickness of the stainless steel heatingelement is from about 0.02 mm to about 0.03 mm, from about 0.02 mm toabout 0.04 mm, from about 0.02 mm to about 0.06 mm, from about 0.02 mmto about 0.08, from about 0.02 mm to about 0.10 mm, from about 0.02 mmto about 0.12 mm, from about 0.02 mm to about 0.16 mm, or from about0.02 mm to about 0.2 mm. In some embodiments, the thickness of thestainless steel heating element is about 0.01 mm, about 0.02 mm, about0.03 mm, about 0.04 mm, about 0.05 mm, about 0.06 mm, about 0.07 mm,about 0.08 mm, about 0.09 mm, about 0.10 mm, about 0.11 mm, about 0.12mm, about 0.13 mm, about 0.14 mm, about 0.15 mm, about 0.16 mm, about0.17 mm, about 0.18 mm, about 0.19 mm or, about 0.20 mm.

The shape of the heating element can enhance the mechanical stability ofthe heating element and thus stability, reproducibility, and performanceof device. The shape of the heating element can contribute to uniformheating of the surface of the heating element by uniform heating ofreplicate heating foils and uniform heating across the heating surface.In some embodiments, the device can achieve a temperature within about 5K, within about 10 K, within about 15 K, within about 20 K, within about25 K, within about 30 K, within about 40 K, or within about 50 K of atarget temperature on greater than about 50%, greater than about 75%,greater than about 90%, greater than about 95%, or greater than about98% of the heating surface. The target temperature can be about 100° C.,about 150° C., about 200° C., about 250° C., about 300° C., about 350°C., about 375° C., about 400° C., about 450° C., or about 500° C. Insome embodiments, there are no detectable hotspots (e.g. greater thanabout 30 K, greater than about 50 K, greater than about 75 K, or greaterthan about 100K over the target temperature) based on thermal imaging.In some embodiments, there no detectable cold spots (e.g. greater thanabout 30 K, greater than about 50 K, greater than about 75 K, or greaterthan about 100K below the target temperature) based on thermal imaging.Similarly, the device can maintain temperature consistency heatingfoils, such that the temperature varies by less than about 2%, less thanabout 5%, or less than about 10%, less than about 5 K, less than about10 less than about 20 K, less than about 25 K, less than about 30 K, orless than about 40 K across batches of 5, 10, 20, 50, 100, or morefoils.

In some embodiments, the heating element can be non-linear. The heatingelement can be shaped like a serpentine pattern like a “U” or a zigzagpattern like an “M”. The shape of the heating element can vary by thenumber of lines that make up the serpentine pattern. For example,multiple connected lines on the heating element can improve themechanical stability, electrical stability, and temperature consistencyof the device. For example, the heating element can be a serpentineshape or a zigzag pattern. The shape of the heating element can have 1,2, 3, 4, 5, 6, 7, 8, 9, 10, or more connected lines arranged in aserpentine or zigzag pattern. In some embodiments, the heating elementcan be shaped as shown in FIG. 1-3. The connected lines on the heatingelement can be separated by gaps of varying angles and distances. Theangle between the connected lines can be from about 1 degree to about180 degrees. In some embodiments, the angles can be 90 degrees, asillustrated in FIGS. 2 and 3. In some embodiments, the heating elementconsists of extremely narrow gaps so that from a distance, the heatingelement appears solid without gaps. The width of the gaps can be about0.1 mm, about 0.15 mm, about 0.2 mm, about 0.25 mm, about 0.3 mm, about0.35 mm, about 0.4 mm, about 0.45 mm, about 0.5 mm, about 0,6 mm, about0.7 mm, about 0.8 mm, about 0.9 mm, or about 1 mm. The small gapsbetween the connected lines of the serpentine or zigzag path can induceefficient electrical flow, The small, intervening gaps can allow airflow to function as an electrical insulator by forcing electrical flowto follow the serpentine electrical path, This electrical flow can allowgeneration of a resistance that is required for effective heating.

FIG. 1 illustrates examples of the foil heating element, The first foil(left) has a serpentine pattern with six connected lines arranged in theserpentine pattern. The middle and right foils have a zigzag patternwith differing numbers of lines arranged in the zigzag pattern. When theheating element is connected to an electrical circuit, the electroncurrent can flow from the negative terminal to the positive terminal.

FIG. 2 illustrates examples of a serpentine-shaped foil heating element.The heating element can range in sizes that are comparable to the sizeof a dime with a diameter of about 17 mm. In some embodiments, thelongest dimension of the foil heating element is less than about 10 mm,less than about 15 mm, less than about 20 mm, or less than about 25 mm.The larger heating element (left) has four connected lines arranged in aserpentine pattern. The heating element (right) has six connected linesarranged in a serpentine pattern. FIG. 3 illustrates an example of aheating element that includes a square or rectangular-shaped heatingsurface and two electrode connections stemming from the bottom of theheating surface (top). The electrode connections that connect theelectrically-resistive heating element to a battery can be made of thesame material and about the same thickness as the heating element. Forexample, the electrode connections can be made of stainless steel. Insome embodiments, the width of the electrode connections can be greaterthan the width of the electrical path. Electrical resistance can scaleas width of the electrical connectors. Accordingly, the width of theelectrode connections can reduce the electrical resistance of theconnection and decrease the heating of the connection, while increasingheating of the foil heating element.

In some embodiments, the area of the heating surface can be greater thanabout 50%, greater than about 75%, greater than about 90%, or greaterthan about 95% of the entire heating element. In some embodiments, thewidth of the gaps between the lines of the heating element (theelectrical path) can be less than about 1×, less than about 0.5×, lessthan about 0.25×, or less than about 0.125× the width of the electricalpath. In some embodiments, the heating surface is about 6 mm by about 6mm. The bottom panel illustrates the heating foil attached to an inertthermally-resistant support (holder) that simultaneously allows for theelectrical connections and mechanically holds the foil in place,cantilevered in the air.

To deter misuse or excessive use of a drug, the invention can includelockout features that prevent repeated dosing within pre-determined timeintervals. Such lockout features can be implemented without requiringeach disposable cartridge to have distinguishing features, to be used inany particular order, or have electronic controls, Instead, the reusablecontroller can record each usage through a timer and can allow only acertain number of uses per pre-determined time interval. For example,the controller can allow use of a maximum of 1 dose per hour.Alternately, the dosage limitation can involve multiple different timeintervals, for example, 1 dose per 30 minutes and no more than 2 dosesper every 4 hours. In some embodiments, the controller can recognize acode, such as a bar code or magnetic code, on the disposable cartridges,and would only heat and vaporize such cartridges, deterring aninappropriate application of the controller to other cartridges notprescribed to the patient. In some embodiments, the controller canrecognize the individual patient, for example, based on a fingerprint,or a passcode.

To deter misuse of a drug in the disposable cartridge, the device canencompass an antagonist of the drug. An antagonist blocks the activityof a drug. For example, an opioid antagonist blocks the activity of anagonist opioid by binding to the opioid receptors. However, theantagonist does not cause an opioid effect. Non-limiting examples ofopioid antagonists include naltrexone, naloxone, nalmefene, andsamidorphan. Non-limiting examples of benzodiazepine antagonists includeflumazenil.

In some embodiments, the portion of the cartridge containing theantagonist is not exposed to the heating element, and vaporization ofthe drug does not co-vaporize the antagonist. In some embodiments, anantagonist of the drug is contained in a heat-resistant compartment ofthe cartridge. Tampering with the device to extract the drug, andcircumvent the control features, can also extract the antagonist. Theantagonist can then mix with the drug and render the drug ineffectivefor abuse.

FIG. 4 illustrates an embodiment of the device. The device comprises ofa cartridge 400 a and a controller 400 b, which can be mechanically andelectrically connected together for operation of the device. Thecontroller 400 b can mate with a single-dose, one-puff, disposablecartridge 400 a.

The cartridge 400 a contains a mouthpiece 401 and a heating element 402containing the drug 402 a. The heating element can be a drug-coated foilas shown in FIG. 4. In some embodiments, the heating element 402contains multiple connected lines arranged in a serpentine shape or azigzag shape. In some embodiments, the width of the exterior lines isthinner than the width of the interior lines. The shape of the heatingelement can pack substantial surface area into a small heating elementwith mechanical strength and high electrical resistance. In contrast, ifthe same serpentine or zigzag line was extended to be a straight line,the mechanical strength would be compromised. Whereas if the shape wasfilled rather than serpentine or zigzag, the electrical resistance maybe less likely to be high enough to effectively heat the foil withoutexcessive risk of shorting or of overheating the battery. In someembodiments, electrical connectors are located near to each other(thereby decreasing the required length of the wires 403 in FIG. 4), onthe same edge of the two-dimensional surface of the heating element 402as shown in the left and middle example of FIG. 1. The controller 400 bcontains a battery 405, an integrated circuit chip 406, a pressuresensor 407, and air inlets 408.

The cartridge 400 a and the controller 400 b are mechanically connectedby a male/female-shaped connection 404 in a manner that forms anelectrical circuit between the cartridge 400 a and the controller 400 b.Electrical currents pass from the controller 400 b to the cartridge 400a through wires 403 connected to the male/female connection 404. Theelectrical connector 404 joins two lengths of wire 403 that create anelectrical circuit between the battery 405 in the controller 400 b andthe heating element 402 in the cartridge 400 a. The wires can be made ofvarious materials including, for example, lead, copper, aluminum, and analloy thereof.

The air inlets of the controller 400 b connect to the airway of thecartridge 400 a, and thereby, connect to the mouthpiece 401. To operatethe device, the cartridge and the controller are mechanically connectedvia connection 404 to create an electrical circuit between the battery405 and the heating element 402. A user can draw or inhale from themouthpiece 401 to initiate heating of the drug-coated foil 402 andsubsequent vaporization of the drug 402 a. The controller 400 b containsa pressure sensor 407 that can sense inhalation when the device is inuse. The pressure sensor 407 senses a pressure change resulting from aninhalation by the user from the mouthpiece 401 and initiates heating ofthe device. Alternatively, flow or convective cooling can be detected toindicate inhalation. In sonic embodiments, once inhalation is sensed,the device goes through a full heating cycle irrespective of continueduser inhalation. In other embodiments, after inhalation is complete, thepressure sensor 407 can detect the pressure change and powers offheating of the device. The air inlets 408 on the controller 400 b allowair to pass from the controller 400 b to the airway of cartridge 400 aand thereby to the mouthpiece 401 and the user.

FIG. 5 illustrates an embodiment of the device. The cartridge 500 acontains a drug-coated foil heating element 502. The layer of drug 502 ais coated on the surface of the heating element 502. The drug 502 a cancover a part of or almost the entirety of the foil heating element 502with margins that are sufficient to avoid overflowing of the drug at theedge of the foil during the coating process. The margin can be at leastabout 0.02 mm, at least about 0.05 mm, at least about 0.1 mm, or atleast about 0.2 mm. The foil heating element is held by one or morethermally-inert support structures 504 that secure the foil within thedevice through physical interaction with its ends, which are inelectrical contact with the wires 503. Alternatively, the wires can bein electrical contact with electrical conductive elements within thesupport, which are in turn in contact with the foil. The supportfunctions to prevent contact between the foil and the exterior of theairway, holding the parts of the foil that are not in contact with thesupport suspended in air. In some embodiments, the serpentine or zigzagaspect of the foil is held cantilevered in air by the support as shownin FIG. 3. In some embodiments, the support 504 comprises or consistsessentially of ceramic. In some embodiments, the support is notelectrically conductive. In some embodiments, the support comprises orconsists essentially of metal. In some embodiments, the majority of thesupport is not electrically conductive and the support comprises metalthat facilitates electrical conduction between the wires 503 and theheated foil 502.

The controller 500 b is mechanically and electrically connected to thecartridge 500 a. The controller 500 b contains a breath sensor 507 inelectronic communication with an integrated circuit chip 506 thatcontrols the voltage and current and a battery 505. The electrical chip506 can also control lockout features that prevent repeated dosingwithin pre-determined time intervals or overdosing. The battery 505 isconnected to the electrical circuit through wires 503 and provideselectricity to heat to the heating element 502. The exterior of thecontroller 500 b contains one or more air inlets 512 that allow air 508a to activate the breath sensor 507 and to pass from the controller intothe cartridge 500 a. The controller element 500 b of the device isreusable and the cartridge 500 a can be disposable.

User inhalation draws air 508 a through the device. Air 508 a flows intothe device and activates the breath sensor 507. The breath sensor sensesthe air movement or pressure change and actuates the passage of electriccurrent from the battery 505 to heat the foil 502. Air flows from thecontroller 500 b into the cartridge 500 a, via a continuous airway whichis formed by mating of the controller 500 b and cartridge 500 a. Airthen passes, optionally through one or more openings, holes, or slits509, across the heated foil 502. The location of slits 509 can be chosento direct air across the heated foil either roughly parallel to or, asshown in FIG. 5, roughly perpendicular to the device axis 511 defined bythe position of the mouthpiece 501 relative to the rear of the assembledmated device 510. In embodiments where the airflow over the foil isroughly perpendicular to the device axis 511, the air flow can be eitherroughly in plane with the heated foil surface 502 as shown in FIG. 5 orperpendicular to the surface. In certain embodiments, airflow from belowto above the coated heated surface 502 decreases degradation of the drug502 a during its heating and vaporization. As the heated foil 502 heatsthe drug 502 a, the drug 502 a vaporizes and condenses in the incomingair 508 a into an aerosol 502 b that is suitable for deep lunginflation. In some embodiments, limiting the airflow over the drug 502 ais desirable so as to increase the particle size of the aerosol.Limiting, the airflow can be achieved by providing a bypass air path508, where the drug can pass from the air intake to the mouthpiece 501without passing over the drug 502 a. The geometry of this air bypass 508can be modulated to control the fraction of air that passes over thedrug 502 a, e.g., in the design shown in FIG. 5, by modulating the sizeof the hole 508.

FIG. 6 illustrates the rate of heating of a heating element usinginfrared thermal imaging. The temperature of the heating elementincreased from about 0° C. to about 130° C. in about 0.12 seconds andincreased from about 130° C. to about 370° C. in about 0.17 seconds.Together, the temperature of the heating element increased from about 0°C. to about 370° C. in about 0.29 seconds. The highest temperaturesrecorded were from about 380° C. to about 430° C. No temperature datawere obtained below 130° C. because the infrared detection limit wasfrom about 130° C. to about 900° C.

Reproducible delivery to the subject can depend on the aerosol particlesize emitted from the device. Particle size is determined by the extentof mixing of the vaporized drug with air, More mixing results in smallerparticle size, and less mixing with larger particle size. The particlesize of the aerosol can depend on the heating rate and air flow over thedrug. The faster the rate of heating, the larger the size of the aerosolparticles. The faster the air flow, the smaller the size of the aerosolparticles. In some embodiments, the particle size or mean particle sizeof a population of particles of an aerosol has a mass median aerodynamicdiameter of about 0.8 μm, about 1 μm, about 2 μm, about 2.5 μm, about 3μm, or about 4 μm. In some embodiments, the airway of the deviceincludes a multiplicity of air passages that direct the proper amount ofairflow over the vaporizing drug. In some embodiments, the deviceincludes one or more air flow control valves that control the airflowover the vaporizing drug and consistently achieve the desired particlesize.

Consistency of the coating can ensure dosage uniformity for the subject,and compliance with regulatory requirements for dose consistency. Insome embodiments, the dose loaded is controlled within about 10%, about5%, about 3%, or about 2% of a prescribed dose through a dip-coating orspray-coating process. The loaded dose can be within about 0.1%, about0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%,about 6%, about 7%, about 8%, about 9%, or about 10% of a prescribeddose.

Another feature of the manufacturing process is compliance withpharmaceutical good manufacturing practice (GMP). GMP provides a systemfor ensuring that products are consistently produced and controlledaccording to quality standards to minimize the risks involved in anypharmaceutical production that cannot be eliminated through testing thefinal product. In some embodiments, the manufacturing process involvesassembly of component parts of the controller and/or disposablecartridge in a factory that does not fully conform to pharmaceuticalGMP, followed by final assembly in a pharmaceutical GMP environment. Forexample, the breath sensor, battery, integrated circuit, or airwayhousing of the controller can be manufactured in one environment, andoptionally connected into larger subassemblies, which undergo finalassembly and/or testing in a pharmaceutical GMP environment. Similarly,the airway housing, electrical connections to the controller, orelectrical connections to the heating element of the disposablecartridge, or the heating element, can be manufactured in oneenvironment, and optionally connected into larger subassemblies, whilethe drug coating and final assembly are conducted in a pharmaceuticalGMP environment.

1. An inhalation device comprising: a) an outer compartment having anairflow pathway therein; b) a cartridge containing a firstpharmaceutical, wherein the cartridge is configured to pass a vapor ofthe first pharmaceutical to the airflow pathway; c) a heating elementhaving a resistance of 0.2-3 Ohm, wherein the heating element isconfigured to heat the first pharmaceutical, wherein the heating elementis configured to be heated by passage of an electrical current; and d)an oral administration port connected to the airflow pathway andconfigured to pass the vapor of the first pharmaceutical from theairflow pathway to a user's mouth.
 2. The inhalation device of claim 1,further comprising a breath sensor wherein the breath sensor isconfigured to activate the heating element upon detection of the user'sbreath.
 3. The inhalation device of claim 1, further comprising abattery having a voltage of 3-4 V, wherein the battery is configured topower the heating element.
 4. The inhalation device of claim 1, whereinthe cartridge further comprises a second pharmaceutical that is anantagonist of the first pharmaceutical, and the heating element isconfigured to minimize vaporization of the second pharmaceutical.
 5. Theinhalation device of claim 1, further comprising a timer, wherein thetimer is configured to disable the passage of current to the heatingelement based on a schedule of use.
 6. The inhalation device of claim 1,wherein the heating element is configured to heat the firstpharmaceutical by pulse width modulation.
 7. The inhalation device ofclaim 1, wherein the heating element comprises an integrated circuitconfigured to heat the first pharmaceutical by pulse width modulation.8. The inhalation device of claim 1, wherein the first pharmaceutical isan opioid agonist.
 9. The inhalation device of claim 1, wherein thefirst pharmaceutical is a benzodiazepine.
 10. The inhalation device ofclaim 1, wherein the first pharmaceutical is a cannabinoid.
 11. Theinhalation device of claim 1, wherein the device comprises a reusableportion comprising the battery and a disposable cartridge, wherein thedisposable cartridge delivers a single dose of the first pharmaceutical.12. A method of administering a compound, the method comprisingadministering the compound by inhalation via an inhalation device, theinhalation device comprising: a) an outer compartment having an airflowpathway therein; b) a cartridge containing a first pharmaceutical,wherein the cartridge is configured to pass a vapor of the firstpharmaceutical to the airflow pathway; c) a heating element having aresistance of 0.2-3 Ohm, wherein the heating element is configured toheat the first pharmaceutical, wherein the heating element is configuredto be heated by passage of an electrical current; and d) an oraladministration port connected to the airflow pathway and configured topass the vapor of the first pharmaceutical from the airflow pathway to auser's mouth.
 13. A kit comprising an inhalation device, wherein the kitcomprises a single reusable portion comprising a battery and a pluralityof disposable cartridges, and the inhalation device comprises a) anouter compartment having an airflow pathway therein; b) a cartridgecontaining a first pharmaceutical, wherein the cartridge is configuredto pass a vapor of the first pharmaceutical to the airflow pathway; c) aheating element having a resistance of 0.2-3 Ohm, wherein the heatingelement is configured to heat the first pharmaceutical, wherein theheating element is configured to be heated by passage of an electricalcurrent; and d) an oral administration port connected to the airflowpathway and configured to pass the vapor of the first pharmaceuticalfrom the airflow pathway to a user's mouth.
 14. The kit of claim 13,further comprising an exterior packaging that encloses both the reusableportion and plurality of the disposable cartridges and an interiorpackaging individually surrounding each of the plurality of disposablecartridges.
 15. The kit of claim 13, wherein the cartridge furthercomprises a second pharmaceutical that is an antagonist of the firstpharmaceutical, and the heating element is configured to minimizevaporization of the second pharmaceutical.
 16. The kit of claim 13,wherein the heating element is configured to heat the firstpharmaceutical by pulse width modulation.
 17. The method of claim 12,wherein the cartridge further comprises a second pharmaceutical that isan antagonist of the first pharmaceutical, and the heating element isconfigured to minimize vaporization of the second pharmaceutical. 18.The method of claim 12, wherein the heating element is configured toheat the first pharmaceutical by pulse width modulation.
 19. Theinhalation device of claim 1, wherein the heating element provides heatsufficient to vaporize at least 90 percent of a coating comprising thefirst pharmaceutical.
 20. The inhalation device of claim 1, wherein theheating element has a non-linear shape.
 21. The inhalation device ofclaim 20, wherein the heating element has a serpentine shape.
 22. Theinhalation device of claim 20, wherein the heating element has a zig-zagshape.